Antepartum screening in the office-based practice : Findings from the collaborative ambulatory research network.
To examine utilization patterns of four antepartum screening tests by office-based obstetricians.
The population surveyed was the Collaborative Ambulatory Research Network, a voluntary subset of 550 ACOG fellows from 130 practices participating in data collection regarding ambulatory practices.
Responses from self-administered questionnaires concerning screening for hepatitis B, gestational diabetes, neural tube defects, and trisomy 21 were analyzed.
Hepatitis screening was performed by all practices with 95% (2750 of 2886) of women tested ; however, only 55% (six of 11) of at-risk newborns received treatment.
For gestational diabetes screening, 94% (116 of 124) administer a 50-g glucose load to all parturients, regardless of risk factors, two-thirds initiate further testing for a 1-hour post-load glucose of 140 mg/dL or greater, and 34% do so at lower glucose levels (130-135 mg/dL).
For neural tube defect screening, 92% (95 of 103) offer maternal serum alphafetoprotein (MSAFP) screening although when results are elevated, further recommendations are varied.
For women under 35 years of age, 84% (87 of 103) offer serum screening for trisomy 21 risk, most (68%) with double or triple (MSAFP, hCG, and estriol) markers.
For women over 35 years, a majority (87%) offer serum screening, although half do so only if amniocentesis is declined for age risk alone. (...)
Mots-clés Pascal : Gestation, Dépistage, Prévention, Hépatite virale B, Virose, Infection, Pratique professionnelle, Diabète, Trisomie, Aneuploïdie, Aberration chromosomique, Chromosome G21, Traitement, Evaluation performance, Homme, Femelle, Appareil génital femelle, Appareil digestif pathologie, Foie pathologie, Endocrinopathie
Mots-clés Pascal anglais : Pregnancy, Medical screening, Prevention, Viral hepatitis B, Viral disease, Infection, Professional practice, Diabetes mellitus, Trisomy, Aneuploidy, Chromosomal aberration, Chromosome G21, Treatment, Performance evaluation, Human, Female, Female genital system, Digestive diseases, Hepatic disease, Endocrinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0459524
Code Inist : 002B30A01A2. Création : 10/04/1997.